3-苯基噌啉-4-羧酸 | 10604-21-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 3-苯基噌啉-4-羧酸
• 英文名称: 3-phenylcinnoline-4-carboxylic acid
• CAS: 10604-21-4
• 化学式: C₁₅H₁₀N₂O₂
• mdl: MFCD00219795
• 分子量: 250.257
• InChiKey: UGJHDXUWDLKCDG-UHFFFAOYSA-N

物化性质

• 熔点：
  216 °C
• 沸点：
  459.6±37.0 °C(Predicted)
• 密度：
  1.332±0.06 g/cm3(Predicted)
• 溶解度：
  11.8 [ug/mL]

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  63.1
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2933990090

SDS

Name:	3-Phenylcinnoline-4-carboxylic acid 97% Material Safety Data Sheet
Synonym:	None Known
CAS:	10604-21-4

Section 1 - Chemical Product MSDS Name:3-Phenylcinnoline-4-carboxylic acid 97% Material Safety Data Sheet
Synonym:None Known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
10604-21-4	3-Phenylcinnoline-4-carboxylic acid	97%	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation. May cause chemical conjunctivitis.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Minimize dust generation and accumulation. Avoid breathing dust, vapor, mist, or gas. Avoid contact with eyes, skin, and clothing.
Keep container tightly closed. Avoid ingestion and inhalation. Use with adequate ventilation. Wash clothing before reuse.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 10604-21-4: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: green
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 232 - 234 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C15H10N2O2
Molecular Weight: 250

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable at room temperature in closed containers under normal storage and handling conditions.
Conditions to Avoid:
Incompatible materials, dust generation.
Incompatibilities with Other Materials:
Bases, reducing agents, strong oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 10604-21-4 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
3-Phenylcinnoline-4-carboxylic acid - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 10604-21-4: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 10604-21-4 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 10604-21-4 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-苯基噌啉-4-羧酸 在 sodium chloride 、 potassium hydroxide 作用下， 以 水 、 二甲基亚砜 为溶剂， 反应 6.0h， 以80%的产率得到3-苯基噌啉
  参考文献：
  名称：

  不同溶剂和激发波长对两种基于苯基肉啉配体的新型 Ir(III) 配合物光物理性质的影响

  摘要：

  两种新型环金属化铱 (III) 配合物 Ir(pcl) 2 (pic) 和 Ir(pcl) 2 (fpic)（pcl：3-苯基肉啉，pic：吡啶甲酸，fpic：5-氟-2-吡啶甲酸）是合成并通过 FTIR、1 H NMR 光谱、UV-vis、PL 和 MALDI-TOF表征。使用 Sparkle/PM6 模型预测了这两种 Ir 配合物几何结构，并建议在 Ir 离子 ( C 1 )周围具有极低对称性的化学环境。Ir(pcl) 2 (pic) 和Ir(pcl) 2的PL光谱(fpic) 表明这些复合物属于红光发射，最大发射波长分别位于 647 和 641 nm。最重要的是，详细研究了不同溶剂对其光致发光性能的影响。结果表明，溶剂的极性对其发射光谱起重要作用。在吡啶环上引入氟基后，Ir(pcl) 2 (fpic)的最大发射波长蓝移了约6 nm，量子产率略高于Ir(pcl) 2 (pic)。此外，

  DOI：

  10.1007/s10895-013-1229-3
• 作为产物：
  描述：

  苯甲醛苯腙 在 potassium hydroxide 作用下， 以 二氯甲烷 、 水 为溶剂， 反应 4.0h， 生成 3-苯基噌啉-4-羧酸
  参考文献：
  名称：

  不同溶剂和激发波长对两种基于苯基肉啉配体的新型 Ir(III) 配合物光物理性质的影响

  摘要：

  两种新型环金属化铱 (III) 配合物 Ir(pcl) 2 (pic) 和 Ir(pcl) 2 (fpic)（pcl：3-苯基肉啉，pic：吡啶甲酸，fpic：5-氟-2-吡啶甲酸）是合成并通过 FTIR、1 H NMR 光谱、UV-vis、PL 和 MALDI-TOF表征。使用 Sparkle/PM6 模型预测了这两种 Ir 配合物几何结构，并建议在 Ir 离子 ( C 1 )周围具有极低对称性的化学环境。Ir(pcl) 2 (pic) 和Ir(pcl) 2的PL光谱(fpic) 表明这些复合物属于红光发射，最大发射波长分别位于 647 和 641 nm。最重要的是，详细研究了不同溶剂对其光致发光性能的影响。结果表明，溶剂的极性对其发射光谱起重要作用。在吡啶环上引入氟基后，Ir(pcl) 2 (fpic)的最大发射波长蓝移了约6 nm，量子产率略高于Ir(pcl) 2 (pic)。此外，

  DOI：

  10.1007/s10895-013-1229-3

文献信息

• Synthesis, Identification, and Structure–Activity Relationship Analysis of GATA4 and NKX2-5 Protein–Protein Interaction Modulators
  作者：Mikael Jumppanen、Sini M. Kinnunen、Mika J. Välimäki、Virpi Talman、Samuli Auno、Tanja Bruun、Gustav Boije af Gennäs、Henri Xhaard、Ingo B. Aumüller、Heikki Ruskoaho、Jari Yli-Kauhaluoma

  DOI：10.1021/acs.jmedchem.9b01086

  日期：2019.9.12

  cytotoxicity. The structure-activity relationship (SAR) analysis revealed that the aromatic isoxazole substituent in the southern part regulates the inhibition of GATA4-NKX2-5 transcriptional synergy. Moreover, inhibition of GATA4 transcriptional activity correlated with the reduced cell viability. In summary, comprehensive SAR analysis accompanied by data analysis successfully identified potent and selective

  转录因子GATA4和NKX2-5直接相互作用并协同激活几种心脏基因和牵张诱导的心肌肥大。以前，我们将苯基异恶唑羧酰胺1确定为命中化合物，该化合物可抑制GATA4-NKX2-5转录协同作用。在此，通过合成和表征220个衍生物和与结构相关的化合物，探索了1分子结构周围的化学空间。除了协同转录激活，还评估了所选化合物对GATA4和NKX2-5转录活性的影响以及潜在的细胞毒性。结构-活性关系（SAR）分析表明，南部的芳族异恶唑取代基可调节对GATA4-NKX2-5转录协同的抑制作用。而且，对GATA4转录活性的抑制与细胞活力的降低有关。总之，综合的SAR分析和数据分析成功地确定了GATA4-NKX2-5转录协同作用的有效和选择性抑制剂，并揭示了对其重要的结构特征。
• Escaping from Flatland: Antimalarial Activity of sp³-Rich Bridged Pyrrolidine Derivatives
  作者：Brian Cox、James Duffy、Victor Zdorichenko、Corentin Bellanger、Jessica Hurcum、Benoît Laleu、Kevin I. Booker-Milburn、Luke D. Elliott、Michael Robertson-Ralph、Christopher J. Swain、Stephen J. Bishop、Irene Hallyburton、Mark Anderson

  DOI：10.1021/acsmedchemlett.0c00486

  日期：2020.12.10

  We utilized synthetic photochemistry to generate novel sp3-rich scaffolds and report the design, synthesis, and biological testing of a diverse series of amides based on the 1-(amino-methyl)-2-benzyl-2-aza-bicyclo[2.1.1]hexane scaffold. Preliminary antimalarial screening of the library provided promising compounds with activity in the 1–5 μM range with an enhanced hit rate. Further evaluation (solubility

  我们利用合成光化学生成了新型富含sp 3 的支架，并报告了基于 1-（氨基-甲基）-2-苄基-2-氮杂-双环 [2.1 .1]己烷支架。该文库的初步抗疟筛选提供了有希望的化合物，其活性范围为 1–5 μM，并具有更高的命中率。所选化合物 ( 9 ) 的进一步评估（溶解度、药物代谢和药代动力学 (DMPK) 和毒性）表明，该系列代表了进一步优化的绝佳机会，该框架为添加独特的矢量定位的额外功能提供了多种机会。
• Substituted heteroaryl pyridopyrimidone derivatives
  申请人：Sanofi-Aventis

  公开号：EP1939187A1

  公开（公告）日：2008-07-02

  A pyrimidone derivative represented by formula (I) or a salt thereof, or a solvate thereof or a hydrate thereof : wherein: Y represents two hydrogen atoms, a sulfur atom, an oxygen atom or a C1-2 alkyl group and a hydrogen atom; Z represents a bond, an oxygen atom, a nitrogen atom, a sulphur atom, a methylene group optionally substituted by one or two groups chosen from a C1-6 alkyl group, a hydroxyl group, a C1-6 alkoxy group, a C1-2 perhalogenated alkyl group or an amino group; R1 represents a 2, 3 or 4-pyridine ring or a 2, 4 or 5-pyrimidine ring; R2 represents a 4-15 membered heterocyclic group , R3 represents a hydrogen atom, a C1-6 alkyl group or a halogen atom; R4 and R5 represent, each independently, a hydrogen atom, a C1-6 alkyl group, optionally substituted by 1 to 4 substituents selected from a halogen atom, a phenyl group, a hydroxyl group or a C1-6 alkoxy group; R6 represents a hydrogen atom, a C1-6 alkyl group ; a cycloalkyl group, or a halogen atom; R7 represents a hydrogen atom or a C1-6 alkyl group; n represents 0 to 3; m represents 0 to 1; o represents 0 to 2; in the form of a free base or of an addition salt with an acid. The invention relates also to a medicament comprising the said derivative or a salt thereof as an active ingredient which is used for preventive and/or therapeutic treatment of a neurodegenerative disease caused by abnormal activity of GSK3β, such as Alzheimer disease.

  公式（I）表示的嘧啶酮衍生物或其盐，溶剂化合物或水合物：其中：Y代表两个氢原子、硫原子、氧原子或C1-2烷基基团和一个氢原子；Z代表键、氧原子、氮原子、硫原子、一个亚甲基基团，可选地由C1-6烷基基团、羟基、C1-6烷氧基、C1-2全卤代烷基或氨基中选择的一种或两种基团取代的亚甲基基团；R1代表2、3或4-吡啶环或2、4或5-嘧啶环；R2代表4-15成员的杂环基团，R3代表氢原子、C1-6烷基基团或卤原子；R4和R5分别代表氢原子、C1-6烷基基团，可选地取代1至4个取代基，所选取代基来自卤原子、苯基、羟基或C1-6烷氧基；R6代表氢原子、C1-6烷基基团；环烷基基团或卤原子；R7代表氢原子或C1-6烷基基团；n表示0到3；m表示0到1；o表示0到2；以自由碱或与酸的加成盐的形式存在。该发明还涉及一种药物，包括所述衍生物或其盐作为活性成分，用于预防和/或治疗由GSK3β异常活性引起的神经退行性疾病，如阿尔茨海默病。
• PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES
  申请人：Aissaoui Hamed

  公开号：US20110212968A1

  公开（公告）日：2011-09-01

  The invention relates to novel phenethylamide derivatives and their wherein A, B, R 1 , R 2 and R 3 are as described in the application, and to the use of such compounds, or of pharmaceutically acceptable salts of such compounds, as medicaments, especially as orexin receptor antagonists.

  本发明涉及新型苯乙酰胺衍生物及其其中A、B、R1、R2和R3如本申请中所述的衍生物的药物学上可接受的盐的使用，特别是作为药物，尤其是作为促进睡眠的药物，如促进睡眠的药物。
• Stolle; Becker, Chemische Berichte, 1924, vol. 57, p. 1124
  作者：Stolle、Becker

  DOI：——

  日期：——